Table 3.
Biodistribution (% injected dose) at various time points of 177Lu2O3-iPSMA in nude mice bearing HCT116 tumors (mean ± SD) (n = 3), after intratumoral injection.
| Tissue | Time (h) | |||
|---|---|---|---|---|
| 3 | 48 | 72 | 96 | |
| Heart | 0.28 ± 0.11 | 0.19 ± 0.07 | 0.10 ± 0.08 | 0.07 ± 0.02 |
| Lung | 0.30 ± 0.10 | 0.21 ± 0.03 | 0.15 ± 0.04 | 0.11 ± 0.07 |
| Liver | 1.05 ± 0.38 | 0.94 ± 0.21 | 0.88 ± 0.12 | 0.84 ± 0.09 |
| Spleen | 0.39 ± 0.16 | 0.34 ± 0.10 | 0.31 ± 0.09 | 0.28 ± 0.07 |
| Kidney | 0.84 ± 0.19 | 0.63 ± 0.23 | 0.58 ± 0.17 | 0.39 ± 0.21 |
| Tumor (%ID/g) | 80.42 ± 5.87 | 79.32 ± 5.27 | 77.23 ± 6.01 | 75.98 ± 5.41 |